Opi-Aid is a protein-based diagnostic for cheaper and more sensitive opioid detection. With over 289 million opioid prescriptions written each year in the U.S. and the public’s eye on the “silent epidemic” of addiction, there is a growing need for drug testing to better control the misuse and abuse of opioids. Currently, opioid testing involves an immunoassay screen; however, the screening antibodies are primarily designed to bind morphine and its derivatives, resulting in large false positive and false negative rates and leading to unnecessary confirmatory testing. The Opi-Aid leverages the binding properties of the opioid receptor; thus, this technology is sensitive not only to all current opioid drugs, but also to future opioid derivatives and analogs. In streamlining and improving the opioid testing process, Opi-Aid will help providers and patients safely alleviate and manage pain.
